Magenta Therapeutics, Inc. MGTA
At closeSep 11, 2023, 4:00 PM EDT
- Market cap
- 47.61M
- EPS (ttm)
- -1.41
- Shares out
- 60.65M
- P/E ratio
- -0.61
- Forward P/E
- 39.25
- Volume
- 375.91K
- Avg volume
- 516.64K
- Open
- 0.7085
- Previous close
- 0.6996
- Day's range
- 0.69 – 0.7589
- 52-week range
- 0.32 – 2.22
- Beta
- 2.12
- Analysts
- Hold
- Price target
- 1.00 (+42.9%)
- Earnings date
- Nov 2, 2023
2Y -7.6304 (-91.60%)
Key statistics
- Enterprise value
- -31.30M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.61
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -44.04M
- Total cash
- 78.21M
- Total debt
- 0
- Return on equity
- -72.32%
- Short % of float
- 1.00%
- 50-day average
- 0.6954
- 200-day average
- 0.8519
Analyst view
Consensus: hold
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 2, 2023
Expected Nov 2, 2023. Consensus EPS estimate -0.19.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 3, 2023 | Jun 1, 2023 | -0.19 | — | — | — |
| Jul 3, 2023 | Mar 1, 2023 | -0.41 | — | — | — |
| Apr 4, 2023 | Dec 1, 2022 | -0.25 | — | — | — |
| Nov 3, 2022 | Sep 1, 2022 | -0.31 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -0.37 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 28, 2023 | HC Wainwright & Co. | init | — | Neutral |
| Jan 26, 2023 | BTIG | down | Buy | Neutral |
| Jan 26, 2023 | Cowen & Co. | down | Outperform | Market Perform |
| Jan 26, 2023 | Wedbush | down | Outperform | Neutral |
| Dec 21, 2022 | BTIG | main | — | Buy |
| Aug 25, 2022 | Goldman Sachs | down | Buy | Neutral |
About Magenta Therapeutics, Inc.
Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- magentatx.com
News
Magenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock Split 
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA 
10 Best-Performing Penny Stocks in the Health Care Sector 
Easing Banking Fears, Rate Hike Pause Boost Markets: 5 Picks 
MGTA Stock: 51.66% Surge Explained 
Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday's Mid-Day Session 
Stocks That Hit 52-Week Lows On Wednesday 
Magenta (MGTA) Down on Pipeline Update for Leukemia Drug 
Why The Magenta Therapeutics (MGTA) Stock Plummeted Over 50% 
Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Your note
Sign in to keep a note on MGTA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEETHAM THOMAS W | Officer | Stock Award(Grant) | Nov 29, 2022 | 19,897 |
| DAVIS JOHN C JR. | Officer | Sale | Jan 1, 2020 | 8,304 |
| DEARDORF CAREN | Officer | Stock Award(Grant) | Nov 29, 2022 | 19,762 |
| GARDNER JASON M PH.D. | Chief Executive Officer | Stock Award(Grant) | Nov 29, 2022 | 944,954 |
| ISACSON CHRISTINA K | Officer | Sale | Dec 23, 2019 | 83,786 |
| MAHONEY STEPHEN F | Chief Operating Officer | Stock Award(Grant) | Nov 29, 2022 | 17,264 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tang Capital Management, LLC | 9.98% | 6,050,000 | 4.75M | Mar 30, 2023 |
| Lion Point Capital, LP | 7.52% | 4,558,466 | 3.58M | Mar 30, 2023 |
| Atlas Venture Life Science Advisors, LLC | 6.25% | 3,791,698 | 2.98M | Mar 30, 2023 |
| Alphabet Inc. | 5.51% | 3,339,138 | 2.62M | Mar 30, 2023 |
| Verition Fund Management, LLC | 3.62% | 2,198,465 | 1.73M | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 3.25% | 1,968,421 | 1.55M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.36% | 1,432,921 | 1.12M | Dec 30, 2022 |
| Vanguard Extended Market Index Fund | 0.76% | 460,025 | 361.12K | Dec 30, 2022 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.35% | 209,500 | 164.46K | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.32% | 193,715 | 152.07K | Feb 27, 2023 |
| Harbor Disruptive Innovation Fund | 0.20% | 120,944 | 94.94K | Jan 30, 2023 |
| iShares Micro Cap ETF | 0.16% | 95,039 | 74.61K | Feb 27, 2023 |